TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03885154

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic Acid (VPA)
Description: IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic Acid (VPA)
Description: IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic Acid (VPA)
Description: IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroergotamine (DHE)
Description: 0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroergotamine (DHE)
Description: 0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroergotamine (DHE)
Description: 0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg
Study: NCT06322550

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cover story
Description: After agreeing to participate, migraine patients were randomly given the briefing information and therefore their group allocation. Patients received the cover stories via the allocated flyer with study information and also by the physician from the outpatient clinic. Fifty percent of patients (Migraine as Patients \[MP\]) received the information that they will take part in a migraine study (compared to healthy controls) and that this study would investigates migraine associated dizziness by watching a visual stimulus (roller coaster video). The protocol for the intervention was standardized and identical for all participants. The other 50% (Migraine as Healthy \[MH\]) received the information that this study was in cooperation with the University's vertigo Department and that they will take part as controls since they were healthy apart from their migraine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cover story
Description: After agreeing to participate, migraine patients were randomly given the briefing information and therefore their group allocation. Patients received the cover stories via the allocated flyer with study information and also by the physician from the outpatient clinic. Fifty percent of patients (Migraine as Patients \[MP\]) received the information that they will take part in a migraine study (compared to healthy controls) and that this study would investigates migraine associated dizziness by watching a visual stimulus (roller coaster video). The protocol for the intervention was standardized and identical for all participants. The other 50% (Migraine as Healthy \[MH\]) received the information that this study was in cooperation with the University's vertigo Department and that they will take part as controls since they were healthy apart from their migraine.
Study: NCT02144571

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle
Description: Participants are consented and randomized into the intervention group or delayed intervention group(intervention offered one year later). Participants in intervention group attend 12 weekly sessions and 9 monthly sessions. All participants attend 3 clinics in which we collect data, measurements and blood samples. These clinics occur at baseline, 12 weeks and one year.
Study: NCT04565340

Intervention type: OTHER
Intervention: Mode of delivery, maternal and neonatal outcomes/complications
Description: Mode of delivery, maternal and neonatal outcomes/complications
Study: NCT01056406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Education
Description: Twice monthly interaction with study nutritionist (a registered dietitian) in the form of face-to-face individual nutrition counseling sessions, telephone and electronic follow-ups, option to attend group nutrition and group exercise classes.
Study: NCT03200197

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menthol chewing gum
Description: The experimental group received one unit of mentholated chewing gum, chewing and swallowing the saliva in a natural rhythm for 10 minutes. The menthol chewing gum used is called TRÍDENT®and is composed as follows: base gum, hydrogenated vegetable oil, vegetable oil, sweeteners: sorbitol, xylitol, mannitol, maltitol, aspartame, acesulfame potassium, and sucralose, humectants: glycerin and triacetin, flavorings (contains wheat derivatives), anti-humectant talc, emulsifiers: esters of mono- and diglycerides of fatty acids with acetic acid, soy lectin and mono and diglycerides of fatty acids and colorings: tartrazine and brilliant blue FCF, presenting a weight of 1.8g per unit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care (fasting)
Description: The control group received the usual care given at the hospitalization units, that is, when the patient reported thirst, the need to maintain fasting for 10 minutes was reaffirmed.
Study: NCT00909441

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Biopsy
Description: Sentinel node biopsy is a technique in which a radioactive isotope is injected in the breast, with or without blue dye. These substances will then migrate and concentrate in the first nodes in the axilla that drain the breast: The sentinel nodes. These nodes (usually one to four nodes) are then evaluated for the presence of cancer cells.
Study: NCT02382731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care + letters
Description: A series of five postal educational reminders sent on behalf of each hospital's interventional cardiology team to the patient approximately 4, 8, 20, 32, and 44 weeks post-MI procedure, with an insert for the family physician and pharmacist at approximately 4 and 8 weeks post-MI procedure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care + letters + automated calls
Description: A series of five postal educational reminders as per the usual care + letters arm plus interactive voice response phone calls to the patient delivered approximately 2 weeks after the letters, as well as personalized telephone follow up by trained lay health workers for patients identified by the interactive voice response system as non-adherent. The automated algorithm is designed to identify patients who are non-adherent and who may benefit from personalized educational phone call and/or system navigation support by the lay health worker. Lay health workers will not provide clinical advice.
Study: NCT03577340

Intervention type: OTHER
Intervention: implant of cardiac device as per guidelines
Description: Observation of performance to validate matrix

Intervention type: OTHER
Intervention: implant of cardiac device as per guidelines
Description: Observation of performance to validate matrix
Study: NCT00282087

Intervention type: DRUG
Group type: OTHER
Intervention: gemcitabine, docetaxel, doxorubicin
Description: Cycles = 28 days
Study: NCT03226249

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo FDG-PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG-PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine Sulfate
Description: Given IV
Study: NCT00094835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m\^2 administered by IV infusion over 3 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m\^2 administered by IV infusion over 3 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was administered IV over approximately 30 minutes. Carboplatin was dosed using the glomerular filtration rate (GFR) and Calvert formula to AUC/time curve of 6 mg/mL×min.
Study: NCT04238091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fecal material transfer therapy
Description: Fecal microbiota transplants will be performed as follows:~FMP Retention Enema: (FMP 250 mL) Dosage Form: Screened human donor stool, suspended in diluent of 12.5% glycerol and sterile normal saline buffer (0.9% NaCl) standardized to a 5X concentration (1g stool : 5mL diluent ratio), homogenized, filtered to 330 microns and aliquoted to sterile 250mL vessels.~Route of Administration: Fecal transplant will be performed under medical supervision. Lubricated enema tube will be inserted into rectum and contents expelled into the distal colon with the subject requested to retain material for a target dwell time of 3 to 24 hours with a mean target of 10 hours. Participants will lie in the left lateral decubitus position but if mobility permits will rotate to supine and right lateral decubitus position.~One half of study subjects will receive a 3 day course of antibiotics prior to fecal transplant, while the other half will not.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fecal material transfer therapy
Description: Fecal microbiota transplants will be performed as follows:~FMP Retention Enema: (FMP 250 mL) Dosage Form: Screened human donor stool, suspended in diluent of 12.5% glycerol and sterile normal saline buffer (0.9% NaCl) standardized to a 5X concentration (1g stool : 5mL diluent ratio), homogenized, filtered to 330 microns and aliquoted to sterile 250mL vessels.~Route of Administration: Fecal transplant will be performed under medical supervision. Lubricated enema tube will be inserted into rectum and contents expelled into the distal colon with the subject requested to retain material for a target dwell time of 3 to 24 hours with a mean target of 10 hours. Participants will lie in the left lateral decubitus position but if mobility permits will rotate to supine and right lateral decubitus position.~One half of study subjects will receive a 3 day course of antibiotics prior to fecal transplant, while the other half will not.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 4mm Punch Biopsy of Scalp
Description: For the skin biopsy, the doctor will select an appropriate area on the scalp (or skin) as the biopsy site. The area will then be numbed (anesthetized). The study doctor or his/hers designee will then use a cylindrical instrument with a sharp edge (similar to a small cookie-cutter) to remove a 4mm cylinder of skin (smaller than the size of a pencil eraser). After the skin is removed, the biopsy site will be closed with absorbable stitches when appropriate. Approximately 2 to 4 stitches may be placed at the wound site to improve healing. Multiple skin punch biopsies may be taken throughout the entire length of the study
Study: NCT00094835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was administered IV over approximately 30 minutes. Carboplatin was dosed using the glomerular filtration rate (GFR) and Calvert formula to AUC/time curve of 6 mg/mL×min.
Study: NCT02479295

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tenckhoff catheter
Description: Peritoneal dialysis catheters for long term use

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tenckhoff catheter
Description: Peritoneal dialysis catheters for long term use
Study: NCT05506696

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fultium
Description: 3200IU Fultium
Study: NCT02954445

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-BCMA-CAR-transduced T cells
Description: The first 3 enrolled patients will receive autologous-derived BCMA-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity, the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
Study: NCT01906476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped Care
Description: Participants will receive an Internet guided cognitive behavioral treatment (iCBT) with support from a telephone coach with the possibility of being stepped up to receiving telephone cognitive behavior therapy (T-CBT) with a therapist

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Cognitive Behavior Therapy
Description: Participants will receive telephone-administered cognitive behavioral therapy (T-CBT).
Study: NCT01755741

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo Vaginal Ring
Description: a silicone elastomer placebo vaginal ring, similar in composition to the dapivirine Ring-004 (which is currently used in IPM's ongoing Phase III program), except that it did not contain any active pharmaceutical agent, and a commercially available standard male latex condom with a silicone-based lubricant.

Intervention type: DEVICE
Group type: OTHER
Intervention: Condom
Description: Male condom

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Condom
Description: Male condom
Study: NCT04298931

Intervention type: OTHER
Intervention: Series of ventilator settings
Description: Before a planned fluid administration, the investigators will apply a series of 10 ventilator settings for 30 seconds each.~The settings are the following combinations of respiratory rate (RR) and tidal volume (TV):~RR (min\^-1), TV (ml/kg predicted body weight)~31, 6~31, 8~24, 6~24, 8~17, 6~17, 8~10, 4~10, 6~10, 8~10, 10~(the order of the respiratory rates: 17 to 31, will be randomized. 10/min will always be last. Tidal volume is always applied from lowest to highest for each respiratory rate).
Study: NCT01887756

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tele Rehabilitation
Study: NCT00647972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine Tablets 20 mg
Description: 20mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyprexa® Tablets 20 mg
Description: 20mg, single dose fasting
Study: NCT01016678

Intervention type: DRUG
Group type: OTHER
Intervention: Treximet
Description: 85mg Imitrex with 500mg Naproxen Sodium combination tablet for treatment of migraine headache. The adult dosage is 1 tab Q12H for migraine and no more than 2 tablets in a 24 hours period.

Intervention type: DRUG
Group type: OTHER
Intervention: Treximet
Description: 85mg Imitrex with 500mg Naproxen Sodium combination tablet for treatment of migraine headache. The adult dosage is 1 tab Q12H for migraine and no more than 2 tablets in a 24 hours period.

Intervention type: DRUG
Group type: OTHER
Intervention: Treximet
Description: 85mg Imitrex with 500mg Naproxen Sodium combination tablet for treatment of migraine headache. The adult dosage is 1 tab Q12H for migraine and no more than 2 tablets in a 24 hours period.

Intervention type: DRUG
Group type: OTHER
Intervention: Treximet
Description: 85mg Imitrex with 500mg Naproxen Sodium combination tablet for treatment of migraine headache. The adult dosage is 1 tab Q12H for migraine and no more than 2 tablets in a 24 hours period.

Intervention type: DRUG
Group type: OTHER
Intervention: Treximet
Description: 85mg Imitrex with 500mg Naproxen Sodium combination tablet for treatment of migraine headache. The adult dosage is 1 tab Q12H for migraine and no more than 2 tablets in a 24 hours period.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Dummy pill comparator

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Dummy pill comparator

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Dummy pill comparator

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Dummy pill comparator
Study: NCT03170258

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Neurofeedback (from fMRI and/or EEG)
Description: During part of the task, a feedback display (e.g., thermometer stimulus) will be used to display the average brain activity for each participant. This signal will be acquired \~ every 1 second during the neurofeedback session and will dynamically update to reflect ongoing changes in brain activity. This continuously updated display is the primary feedback mechanism provided to the participant.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurofeedback (from fMRI and/or EEG)
Description: During part of the task, a feedback display (e.g., thermometer stimulus) will be used to display the average brain activity for each participant. This signal will be acquired \~ every 1 second during the neurofeedback session and will dynamically update to reflect ongoing changes in brain activity. This continuously updated display is the primary feedback mechanism provided to the participant.
Study: NCT03214328

Intervention type: DIAGNOSTIC_TEST
Intervention: Determination of causes of fetal death
Description: Determination of causes of fetal death using systematic protocol testing
Study: NCT02081560

Intervention type: DRUG
Group type: OTHER
Intervention: Colistin
Description: Colistin i.v. three times daily as long a necessary for infection treatment
Study: NCT02999191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1467335 (Treatment A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1467335 (Treatment B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1467335 (Treatment C)
Study: NCT03489070

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Traumastem®
Description: Intraoperative application as secondary hemostatic treatment

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Surgicel®
Description: Intraoperative application as secondary hemostatic treatment
Study: NCT03375970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TCM
Description: oral chinese herb, chinese topical ointment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Western medicine
Description: oral steroid, oral antihistamine, topical steroid

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Western medicine
Description: oral steroid, oral antihistamine, topical steroid
Study: NCT00045591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: 100 mg PO bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 400 mg PO bid
Study: NCT04637191

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MentalPlus®
Description: A digital game named MentalPlus will be used to evaluate the possibility of this game becoming a neuropsychological test.
Study: NCT00003613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O6-benzylguanine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: Given topically

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00224783

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CAIV-T
Description: Trivalent cold adapted temperature sensitive attenuated Types A and Type B influenza virus live vaccine (CAIV-T)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.2 mL of 0.01 mol/L potassium phosphate buffer containing 0.85% sodium chloride (pH 7.2).
Study: NCT01333098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: 300mg per day, by mouth, for 21-28 days
Study: NCT01761136

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inoculation in upper arm deltoid
Description: Inoculation of Hib vaccine of two brands in upper arm deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inoculation in upper arm deltoid
Description: Inoculation of Hib vaccine of two brands in upper arm deltoid

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inoculation in vastus lateralis muscle
Description: Inoculation of Hib vaccine of two brands in vastus lateralis muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inoculation in vastus lateralis muscle
Description: Inoculation of Hib vaccine of two brands in vastus lateralis muscle
Study: NCT05459480

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the jigsaw technique in web-based distance education
Description: The online training for the intervention group continued for a total of 6 weeks according to the jigsaw technique.
Study: NCT03385694

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment
Description: Pelvic coronal X-ray, proprioceptive test with Delos system, questionnaires administration, orthopaedic, physiatric and prosthetic assessment
Study: NCT00954057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIPO-102
Description: intraorbital injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intraorbital injection
Study: NCT01673269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood culture ( aerobic and anaerobic)
Description: Blood culture 5 minutes and 30 minutes after the procedure
Study: NCT04474197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-864
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-864
Description: Tablets for oral administration.
Study: NCT04422353

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Dance classes
Description: The dance program consists of dance lessons inspired by Forró rhythm and Samba rhythm. The classes will be held through a recorded video that must be played twice a week. Each video class lasts 30 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unsupervised physical activities
Description: The classes will be held through a recorded video that must be played twice a week. Each video class lasts 30 minutes.
Study: NCT02955381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Silk, 1.0 ml
Description: Restylane® Silk was approved in 2014 submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.
Study: NCT04474197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-864
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to VX-864 for oral administration.
Study: NCT04110054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-600918
Description: Tablets for oral administration
Study: NCT02955381

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Saline, 1.0 ml
Description: Simple saline solution. To be used as placebo (control). No active ingredients.
Study: NCT00604123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-17166864
Description: JNJ-17166864 0.5 mg per nostril twice daily for 2 weeks.